Radient Pharmaceuticals Corp (RPC), through its US-based subsidiary AMDL Diagnostics, has signed an exclusive 5-year sales, marketing and distribution agreement with US-based multinational biotechnology company Jaiva Technologies (JT) and its affiliate Gaur Diagno (GD, New Delhi), collectively referred to as JTGD.
Under the terms of the agreement, JTGD has the exclusive rights to distribute RPC’s Onko-Sure in vitro diagnostic cancer test in India and will be responsible for product sales, marketing and government regulatory in the territory.
Onko-Sure is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic test that enables physicians and their patients to monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP).
Onko-Sure is approved by the FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer screen and cancer monitoring tool.
JTGD anticipates receiving Indian government support in various regions to implement the Onko-Sure cancer test as a cancer screening tool for populations at risk.
Radient claimed that this will be the first large scale Onko-Sure cancer testing/screening initiative. JTGD has initiated Onko-Sure cancer testing in hospitals and cancer clinics throughout India. The agreement is RPC’s cornerstone and guide for developing a broader government backed health-care strategy to encourage widespread screening of population sat cancer risk.
Umesh Bhatia, CEO of JTGD, said: “Onko-Sure is being well accepted by the Indian Medical community. We’ve already seen the impact that Onko-Sure is making in saving patient lives. Onko-Sure, when used as a general screen, was able to identify early-stage cancers that were otherwise missed by standard tests. We expect Onko-Sure will become the leading cancer test and early screening tool in India.”
Douglas MacLellan, chairman and CEO of RPC, said: “This new distribution agreement with JTGD provides Radient Pharmaceuticals with a path for the first large scale use of the Onko-Sure cancer test as a general cancer screening tool.
“This initial general cancer screening program is the first step in moving Onko-Sure into becoming a generally accepted cancer screening tool throughout critical healthcare markets where such diagnostics will have a positive effect on patient care.”